Gilead Sciences D
D
GILD
110.760
USD
-0.76
(-0.68%)
مغلق
حجم التداول
144,536
الربح لكل سهم
8
العائد الربحي
2.79
P/E
23
حجم السوق
137,777,589,442
الأخبار المقالات
العنوان: Gilead Sciences
القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).